Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250198 | 1.00 | CTSB (0.36) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL8250133 | 1.00 | CTSB (0.36) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL12383127 | 0.91 | CTSS (0.35) | CTSS | |
| SCHEMBL11888410 | 0.91 | CTSS (0.35) | CTSS | |
| SCHEMBL10156683 | 0.90 | CTSS (0.42) | CTSBPPP3CBCTSS | |
| SCHEMBL2449092 | 0.89 | CTSB (0.35) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL11887180 | 0.89 | CTSB (0.35) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL13385448 | 0.88 | CTSS (0.35) | CTSS | |
| SCHEMBL2212114 | 0.88 | CTSB (0.41) | CTSBPPP3CBCTSS | |
| SCHEMBL8248937 | 0.88 | CTSB (0.41) | CTSBPPP3CBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CTSB 404/4885PPP3CB 1055/4885CTSS 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.